Johnson & Johnson vs Pfizer: Which Is the Better Buy in 2026?

J&J's post-spin structure is important context. After divesting its consumer segment into Kenvue, what's left is medtech (surgical devices, orthopedics, diagnostics) and pharmaceuticals. Both with strong recurring revenue characteristics. Pfizer's issue is that its COVID-era revenue was extraordinary and non-recurring, which makes comps brutal and investors skeptical about normalized earnings power. The pipeline has to prove itself on its own merits now.

The comparison became cleaner after J&J spun off its consumer division. What remains is a focused medtech and pharma business with predictable, diversified cash flow. Pfizer is navigating the other side of a COVID revenue cliff, with investors waiting to see whether its oncology pipeline can fill the gap that Paxlovid and vaccine revenue left. J&J for quality and consistency; Pfizer for a beaten-down value bet on pipeline execution.